CAPRWin

CAPR Win

We follow a wide range of biotechs, and CAPR has been on our radar for months. When we saw a sudden price move on strong volume, we established a substantial position. This wasn’t chance it was our edge.

We began building our position on November 28th, with an initial buy at $5.17. As I write this note, the position is now up 383%.

Our advantage is simple:

Identifying strong science early before the rest of the market wakes up.

CAPR is a perfect example of how our strategy works. We spot breakthrough potential at the quiet stage, long before it becomes a headline.

More early wins ahead, hopefully.